300
Participants
Start Date
November 20, 2023
Primary Completion Date
August 31, 2026
Study Completion Date
May 31, 2027
Gabapentin
Dosing will be titrated up over 3 weeks, starting with a daily dose of 300mg (1 capsule/day) in week 1, followed by a daily dose of 900mg (3 capsules/day) in week 2, up to a target daily dose of 1800mg (6 capsules/day) in week 3. The target dose of 1800mg per day will be sustained from weeks 3 through day 4 of week 12. Then, dose will be tapered down to 900mg in days 5-7 of week 12, and medication will be discontinued at the end of week 12.
Placebo
Participants randomized to this group will receive a placebo medication for 3 months and will be instructed to follow the same pill regimen as the intervention arm.
RECRUITING
Mbarara Regional Referral Hospital (MRRH): Immune Suppression Syndrome HIV, Mbarara
Lead Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Boston Medical Center
OTHER